Dalcetrapib: meta-analysis of COVID-19 studies

0 0.5 1 1.5+ All studies -134% 1 208 Improvement, Studies, Patients Relative Risk Mortality -134% 1 208 Ventilation -134% 1 208 Hospitalization -37% 1 208 RCTs -134% 1 208 Early -134% 1 208 Dalcetrapib for COVID-19 c19early.org December 2025 Favorsdalcetrapib Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Kallend (DB RCT) -134% 2.34 [0.10-56.6] death 1/155 0/53 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.61 Early treatment -134% 2.34 [0.10-56.6] 1/155 0/53 134% higher risk All studies -134% 2.34 [0.10-56.6] 1/155 0/53 134% higher risk 1 dalcetrapib COVID-19 study c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.61 Effect extraction pre-specified(most serious outcome) Favors dalcetrapib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Kallend (DB RCT) -134% 2.34 [0.10-56.6] 1/155 0/53 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.61 Early treatment -134% 2.34 [0.10-56.6] 1/155 0/53 134% higher risk All studies -134% 2.34 [0.10-56.6] 1/155 0/53 134% higher risk 1 dalcetrapib COVID-19 mortality result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.61 Favors dalcetrapib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Kallend (DB RCT) -134% 2.34 [0.10-56.6] 1/155 0/53 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.61 Early treatment -134% 2.34 [0.10-56.6] 1/155 0/53 134% higher risk All studies -134% 2.34 [0.10-56.6] 1/155 0/53 134% higher risk 1 dalcetrapib COVID-19 mechanical ventilation result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.61 Favors dalcetrapib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Kallend (DB RCT) -37% 1.37 [0.30-6.24] hosp. 8/155 2/53 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.7 Early treatment -37% 1.37 [0.30-6.24] 8/155 2/53 37% higher risk All studies -37% 1.37 [0.30-6.24] 8/155 2/53 37% higher risk 1 dalcetrapib COVID-19 hospitalization result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.7 Favors dalcetrapib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Kallend (DB RCT) -134% 2.34 [0.10-56.6] death 1/155 0/53 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.61 Early treatment -134% 2.34 [0.10-56.6] 1/155 0/53 134% higher risk All studies -134% 2.34 [0.10-56.6] 1/155 0/53 134% higher risk 1 dalcetrapib COVID-19 Randomized Controlled Trial c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.61 Effect extraction pre-specified(most serious outcome) Favors dalcetrapib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Kallend (DB RCT) -134% 2.34 [0.10-56.6] 1/155 0/53 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.61 Early treatment -134% 2.34 [0.10-56.6] 1/155 0/53 134% higher risk All studies -134% 2.34 [0.10-56.6] 1/155 0/53 134% higher risk 1 dalcetrapib COVID-19 RCT mortality result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.61 Favors dalcetrapib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Kallend (DB RCT) -134% 2.34 [0.10-56.6] death 1/155 0/53 Improvement, RR [CI] Treatment Control Kallend (DB RCT) -134% 2.34 [0.10-56.6] ventilation 1/155 0/53 Kallend (DB RCT) -139% 2.39 [0.30-19.0] oxygen 7/155 1/53 Kallend (DB RCT) -37% 1.37 [0.30-6.24] hosp. 8/155 2/53 Dalcetrapib COVID-19 outcomes c19early.org December 2025 Favors dalcetrapib Favors control